Anxiety Flashcards
1
Q
SSRI (Antidepressant)
Common indications
A
- Moderate-to-severe depression and in mild depression if psychological treatment fails
- Pain disorder
- OCD
2
Q
SSRI (Antidepressant)
MOA
A
- SSRI preferentially inhibit neuronal reuptake of serotonin (5-HT) from the synaptic cleft, thereby increasing its availability for neurotransmission
- This appears to be the mechanism by which SSRIs improve mood and physical symptoms in depression and relieve symptoms of panic and OCD
- SSRIs differ from TCA in that they do not inhibit NA uptake and cause less blockade of other receptors
- The efficacy of the 2 drug classes in the treatment of depression is similar
- However, SSRIs are generally preferred as they have fewer adverse effects and are less dangerous in overdose
3
Q
SSRI (Antidepressant)
Adverse effects
A
- Common adverse effects include: GI upset, appetite and weight disturbance (loss or gain) and hypersensitivity reactions, including skin rash
- Hyponatraemia is an important adverse effect, particularly in the elderly, and may present with confusion and reduced consciousness
- Suicidal thoughts and behaviour may be increased in patients on SSRIs
- SSRI lower the seizure threshold and some (e.g. citalopram) prolong QT interval and can predispose to arrhythmias
- SSRIs also increase the risk of bleeding
- At high doses, in overdose, or in combination with other antidepressant classes, SSRI cause serotonin syndrome
- This triad of autonomic hyperactivity, altered mental state and neuromuscular excitation, which usually responds to treatment withdrawal and supportive therapy
- Sudden withdrawal of SSRI can cause GI, neurological, influenza-like symptoms and sleep disturbance
4
Q
SSRI (Antidepressant)
Warnings
A
- SSRIs should be prescribed with caution where there is a particular risk of adverse effects, including in epilepsy and peptic ulcer disease
- In young people, SSRIs have poor efficacy and are associated with an increased risk of self-harm and suicidal thoughts, so should only be prescribed by a specialists
- As SSRIs are metabolised by the liver, dose reduction may be required in people with hepatic impairment
5
Q
SSRI (Antidepressant)
Important interactions
A
- SSRIs should not be given with MAOI as they both increase synaptic serotonin levels and together may precipitate serotonin syndrome
- Gastroprotection should be prescribed for patients taking SSRIs with aspirin and NSAIDs due to an increased risk of GI bleeds
- Bleeding risk is also increased where SSRIs are co-prescribed with anticoagulants
- They should not be combined with other drugs that prolong the QT interval, such as antipsychotics
6
Q
SSRI (Antidepressant)
Communication
A
- Advise patients that treatment should improve symptoms over a few weeks, particularly sleep and appetite
- Discuss referring them for psychomotor therapy, which may offer more long-term benefits than drug treatment
- Explain that they should carry on with drug treatment for at least 6 months after they feel better to stop the depression from coming back (2 years for recurrent depression)
- Warn them not to stop treatment suddenly as this may cause GI upset, flu-like symptoms and withdrawal symptoms and sleeplessness
- When the time comes to stop treatment, they should reduce the dose slowly over 4 weeks
- While patients may find some of the more common side effects unpleasant, they may tolerate them in favour of relieving depressive symptoms
- Discussing at an early stage what side effects are expected may encourage patients to persist with treatment, at least until the full antidepressant effects are realised
7
Q
Venlafaxine and mirtazapine
Common indications
A
- As an option for treatment of major depression where the first-line SSRI are ineffective or not tolerated
- Generalised Anxiety disorder
8
Q
Venlafaxine and mirtazapine
MOA
A
- Venlafaxine is a serotonin and NA reuptake inhibitor (SNRI), interfering with the uptake of these neurotransmitters from the synaptic cleft
- Mirtazapine is an antagonist of inhibitory pre-synaptic a2-adrenoreceptor
- Both drugs increase the availability of monoamines for neurotransmission, which appears to be the mechanism whereby they improve mood and physical symptoms in moderate-to-severe (but not mild) depression
- Venlafaxine is a weaker antagonist of muscarinic and histamine receptors than TCA, whereas mirtazapine is a potent antagonist of histamine (H1) but not muscarinic receptors
- They therefore have fewer antimuscarinic side effects than TCA although mirtazapine is sedating
9
Q
Venlafaxine and mirtazapine
Adverse effects
A
- Common adverse effects of both drugs include GI upset (dry mouth, nausea, change in weight and diarrhoea or constipation) and central nervous system effects (e.g. headache, ab dreams, insomnia, confusion and convulsions)
- Less common but serious adverse effects include hyponatraemia and serotonin syndrome
- Suicidal thoughts and behaviour may increase
- Venlafaxine prolongs the QT interval and can increase the risk of ventricular arrhythmias
- Sudden drug withdrawal can cause GI upset, neurological and influenza-like symptoms and sleep disturbance
- Venlafaxine is associated with a greater risk of withdrawal effects than other antidepressants
10
Q
Venlafaxine and mirtazapine
Warnings
A
- As with many centrally-acting medications, the elderly are at particular risk of adverse effects
- A dose reduction should be considered in people with hepatic or renal impairment
- Venlafaxine should be used with caution (if at all) in patients with CVD associated with an increased risk of arrhythmias
11
Q
Venlafaxine and mirtazapine
Important interactions
A
- The combination of these drugs with drugs from other antidepressant classes can increase the risk of adverse effects (including serotonin syndrome)
12
Q
Venlafaxine and mirtazapine
Communication
A
- Advise patients that treatment should improve symptoms over a few weeks, particularly sleep and appetite
- Discuss referring them for psychological therapy, which may offer more long-term benefits than drug treatment
- Explain that they should carry on with drug treatment for at least 6 months after they feel better to stop the depression from coming back (2 years for recurrent depression)
- Warn them not to stop treatment suddenly as this may cause withdrawal symptoms and sleeplessness
- When the time comes to stop treatment, they should reduce the dose slowly over 4 weeks
- warn patients taking mirtazapine to seek medical advice for symptoms of infection such as sore throat, blood tests for disorders
13
Q
Venlafaxine and mirtazapine
Monitoring
A
- Symptoms should be reviewed 1-2 weeks after starting treatment and regularly thereafter
- If no effect has been seen at 4 weeks, you should consider changing the dose or drug
- Otherwise, the dose should not be adjusted until after 6-8 weeks of therapy
14
Q
SEE alcohol withdrawal for BZ
A
15
Q
Gabapentin and Pregabalin
Common indications
A
- Both drugs are used for focal epilepsies (with or without secondary generalisation), usually, as an add-on treatment .when other anti-epileptic drugs (e.g. CBZ) provide inadequate control
- Both drugs are used for neuropathic pain; pregabalin , in particular, is recommended as a 2nd-line option in painful diabetic neuropathy (after duloxetine) and as a first-line option in other painful neuropathies
- Gabapentin is used in migraine prophylaxis
- Pregabalin is used in GAD